Live
Provision of Assay Kits for SCID & SMA In-Service Evaluations - EONIS-Q Revvity
£4,074,117
goods
Contract Details
- Tender Value
- £4,074,117
- Stage
- Live
- Published
- Awarded
Timeline
Disclosed
Awarded
Start
End
Description
EONIS-Q Assay methodology, as part of the delivery and implementation of the ongoing NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID) in 4 Screening laboratories, with the addition of the ISE for Spinal Muscular Atrophy (SMA).
Related Contracts
From This Buyer
From This Supplier
In This Category
Ref: d1d6ec3d-8b57-42c2-bcc9-988c98df5b88-888234 · Sourced from Contracts Finder
View source notice